ISN Journal editorial selections on dapagliflozin, Thailand’s CKD strategy, and misleading pseudocrescents in glomerulopathy
Kidney International® New insights from DAPA-CKD indicate that dapagliflozin modulates key pathways related to kidney outcomes Dapagliflozin improves kidney outcomes in chronic kidney disease (CKD), but the mechanisms behind these benefits are not fully understood. This DAPA-CKD proteomic analysis found that dapagliflozin modifies biological pathways linked to CKD progression, particularly those involving inflammation, fibrosis, and tissue remodeling. The...
